Global /Taiwan /Healthcare /Drug Manufacturers - Specialty & Generic /6935

Prince Pharmaceutical Co., Ltd.

6935

• TPEX: 6935 • Delayed

29.75TWD 2.6%

0.9408 USD

As of 14 June 2026, Prince Pharmaceutical Co., Ltd. has a market cap of $33.61M USD, ranking #33454 globally and #2053 in Taiwan. It ranks #3020 in the Healthcare sector, and #178 in the Drug Manufacturers - Specialty & Generic industry.

Global Rank

33454

Country Rank

2053

Sector Rank

3020

Industry Rank

178

Key Stats

Market Cap

$33.61MUSD

1.06B TWD

Enterprise Value

$42.09MUSD

1.33B TWD

Revenue (TTM)

$33.44MUSD

1.06B TWD

EBITDA (TTM)

$5.17MUSD

163.6M TWD

Net Income (TTM)

$3.05MUSD

96.32M TWD

EBITDA Margin

15%

Profit Margin

9.1%

PE Ratio

11.1

PS Ratio

1.0

PB Ratio

1.3

EV/EBITDA

7.7

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Da Li open_in_new

Employees

216

Founded

1962

Website

prince-pharm.com.tw open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
2.6%	-3.5%	4.7%	-5.2%	-12%	-6.8%	38%	-36%	-15%

News

Markets

Exchange	Ticker	Price	Quotes
Taipei Exchange (TPEX) MIC: ROCO PRIMARY	6935 王子製藥股份有限公司 ISIN: TW0006935000 Shares Out.: Shares Outstanding: 37.41M¹ TV: TradingView: TPEX: 6935 SA: Stock Analysis: TPEX: 6935 YF: Yahoo Finance: 6935.TWO GF: Google Finance: TPEX: 6935 BA: Barron's: 6935 MS: Morningstar: ROCO: 6935	29.75 TWD	TV: TradingView: TPEX: 6935 SA: Stock Analysis: TPEX: 6935 YF: Yahoo Finance: 6935.TWO GF: Google Finance: TPEX: 6935 BA: Barron's: 6935 MS: Morningstar: ROCO: 6935

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Prince Pharmaceutical Co., Ltd.

Prince Pharmaceutical Co., Ltd. manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally. The company also offers health food and medicines; vitamin c tablets, vitamin b complex tablets, natto and rhodiola extract capsules, probiotic sachets, and plant extract capsules; and API products comprising felbinac, aldioxa, tulobuterol, ufenamate, bisbentiamine, thiamine disulfide, potassium guaiacolsulfonate, potassium cresolsulfonate, fusultiamine hydrochloride, and fursultiamine. Prince Pharmaceutical Co., Ltd. was founded in 1962 and is headquartered in Yúnlín, Taiwan.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
Bora Pharmaceuticals Co., Ltd. TWSE: 6472	$1.68B 52.95B TWD 5K%	17.9	Taiwan
Grape King Bio Ltd. TWSE: 1707	$534.74M 16.89B TWD 1K%	14.0	Taiwan
Daiken Biomedical Co., Ltd. TWSE: 7780	$474.5M 14.99B TWD 1K%	36.5	Taiwan
TCI Co., Ltd. TPEX: 8436	$413.43M 13.06B TWD 1K%	13.7	Taiwan
Microbio Co., Ltd. TPEX: 4128	$290.54M 9.18B TWD 764%	-	Taiwan
Intelligene Inc. TPEX: 7832	$243.34M 7.69B TWD 624%	-	Taiwan

Industry: Drug Manufacturers - Specialty & Generic (Global)

Name	Market Cap (USD) diff.	PE	Country
Teva Pharmaceutical Industries Ltd. TLV: TEVA	$36.75B 108.92B ILS 109K%	24.2	Israel
Revolution Medicines, Inc. NASDAQ: RVMD	$29.56B 88K%	-	United States
Zhejiang NHU Company Ltd. SHE: 002001	$15.84B 107.34B CNY 47K%	16.0	China
Cipla Ltd. NSE: CIPLA	$11.16B 1.06T INR 33K%	23.4	India
Lupin Ltd. NSE: LUPIN	$11.04B 1.05T INR 33K%	22.7	India
Haisco Pharmaceutical Group Co., Ltd. SHE: 002653	$9.09B 61.6B CNY 27K%	80.6	China

chevron_leftBack